High-dose Chemotherapy with Stem Cell Rescue Provided Durable Remission for Classical Hodgkin Lymphoma-type Post-transplant Lymphoproliferative Disorder after Unrelated Cord Blood Transplantation: A Case Report and Review of the Literature

Intern Med. 2017;56(14):1873-1877. doi: 10.2169/internalmedicine.56.7938. Epub 2017 Jul 15.

Abstract

An adult woman developed polymorphic post-transplant lymphoproliferative disorder (PTLD) 58 months after unrelated cord blood transplantation. She was treated successfully with chemotherapy and radiation therapy but presented with lymphadenopathy and splenomegaly 74 months after transplantation. A lymph node biopsy confirmed the diagnosis of nodular sclerosis type Hodgkin lymphoma (classical Hodgkin lymphoma [CHL]-type PTLD). After salvage therapy and hematopoietic stem cell harvesting, she was subsequently treated with consolidative high-dose chemotherapy with melphalan followed by stem cell rescue, which resulted in durable remission. High-dose chemotherapy using stem cell rescue has potential as a therapeutic option for subsequent CHL-type PTLD.

Keywords: Classical Hodgkin lymphoma; high-dose chemotherapy; post-transplant lymphoproliferative disorder; unrelated cord blood transplantation.

Publication types

  • Case Reports

MeSH terms

  • Female
  • Fetal Blood
  • Hematopoietic Stem Cell Transplantation / methods*
  • Hodgkin Disease / complications
  • Hodgkin Disease / therapy*
  • Humans
  • Lymphoproliferative Disorders / complications
  • Lymphoproliferative Disorders / etiology
  • Lymphoproliferative Disorders / therapy*
  • Melphalan / administration & dosage
  • Melphalan / therapeutic use*
  • Middle Aged
  • Salvage Therapy / methods*

Substances

  • Melphalan